WILSON SONSINI

David Stanton

ASSOCIATE

Patents and Innovations

Washington, D.C.

dstanton@wsgr.com
202-973-8812

FOCUS AREAS

Biotech

Intellectual Property

Life Sciences

Patents and Innovations

EXPERIENCE

David Stanton is an associate at Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. David works with biotechnology, pharmaceutical, and life science clients on the development of IP strategy, drafting and prosecuting patent applications, conducting IP due diligence, and working on related business matters. David works with innovators in a variety of technical fields, including genetic and epigenetic editing, cell therapies, immunotherapeutics, pharmaceuticals, and medical devices.

Prior to joining the firm, David earned a Ph.D. in biomedical sciences from West Virginia University, where his doctoral research focused on the development of transcriptional and metabolic dysfunction within peripheral tissues induced by breast cancer growth. During this time, he developed technical expertise in cell and molecular biology, biochemistry, physiology, cancer cell biology, and related fields.

CREDENTIALS

Education

- J.D., West Virginia University College of Law, 2025
- Ph.D., Biomedical Sciences, West Virginia University, 2021
- M.S., Exercise Physiology, West Virginia University, 2017
- B.S., Athletic Training, West Virginia Wesleyan College, 2015

Admissions

- Bar of the District of Columbia
- U.S. Patent and Trademark Office

INSIGHTS

Select Publications

- Co-author with H.E. Wilson, S. Rellick, W. Geldenhuys, and E.E. Pistilli, “Breast cancer-associated skeletal muscle mitochondrial dysfunction and lipid accumulation is reversed by PPARG,” *American Journal of Physiology- Cell Physiology,* 2021
- Co-author with H.E. Wilson, C. Montgomery, A.M. Infante, M. Taylor, H. Hazard-Jenkins, E.N. Pugacheva, and E.E. Pistilli, “Skeletal muscle reprogramming by breast cancer regardless of treatment history or tumor molecular subtype,” *NPJ Breast Cancer*, 2020
- Co-author with H.E. Wilson, K.K. Rhodes, D. Rodriguez, I. Chahal, J. Bohlen, M. Davis, A.M. Infante, H. Hazard-Jenkins, D.J. Klinke, E.N. Pugacheva, and E.E. Pistilli, “Human Breast Cancer Xenograft Model Implicates Peroxisome Proliferator-activated Receptor Signaling as Driver of Cancer-induced Muscle Fatigue,” *Clin Cancer Res.,* 2019
- Co-author with M.J. Myers, D.L. Shepherd, A.J. Durr, J.S. Mohamed, J.M. Hollander, and S.E. Alway, “The role of SIRT1 in skeletal muscle function and repair of older mice,” *J Cachexia*

Sarcopenia Muscle, 2019
- Co-author with S. Haramizu, S. Asano, D.C. Butler, A. Hajira, J.S. Mohamed,and S.E. Alway, "Dietary resveratrol confers apoptotic resistance to oxidative stress in myoblasts," *J Nutr Biochem.*, 2017

TECHNICAL FLUENCY

Biological Sciences and Biotechnology

- Antibody
- Biochemistry
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Immunology
- Molecular biology
- T cell biology

Therapeutics and Drug Discovery

- CRISPR
- Drug delivery
- Gene editing
- Gene therapy
- Immunotherapy targets

Diagnostics and Medical Devices

- Biomedical devices

Genomics and Data Analysis

- shRNA
- Single-cell sequencing

Miscellaneous

- Cancer
- Formulations
- Physical therapy
- Physiology